VTCN1 Antibody | 7189

VTCN1 Antibody | 7189 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse

Homology: Predicted species reactivity based on immunogen sequence: Rat: (83%)

Immunogen: Rabbit polyclonal VTCN1 antibody was raised against an 18 amino acid peptide near the center of human VTCN1.
The immunogen is located within amino acids 70 - 120 of VTCN1.

Research Area: Innate Immunity

Tested Application: E, WB

Application: VTCN1 antibody can be used for detection of VTCN1 by Western blot at 1 - 2 μg/mL.
Antibody validated: Western Blot in mouse samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1287 - EL4 Cell Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: Predicted: 31 kDa

Validation: N/A

Isoform: N/A

Purification: VTCN1 Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: VTCN1 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: VTCN1 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year.

Alternate Name: VTCN1 Antibody: B7X, B7H4, B7S1, B7-H4, B7h.5, VCTN1, PRO1291, UNQ659/PRO1291, V-set domain-containing T-cell activation inhibitor 1, Immune costimulatory protein B7-H4

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: VTCN1 Antibody: T cell immunity plays a critical role in host immune surveillance of tumour cell growth and metastatic spread. VTCN1, also known as B7-H4, is a member of the B7 family of immune regulatory molecules. Expressed primarily on the membrane of lymphoid cells, VTCN1 is an immunoinhibitory protein that interacts with receptors on the surface of T lymphocytes, thus mediating cellular and humoral immune responses. Overexpression of VTCN1 is associated with certain malignancies, including ovarian and breast cancer, which may be a mechanism by which tumour cells suppress T cell immunity and facilitate tumour progression. VTCN1 may thus be a useful biomarker for the early detection of ovarian cancer.